합성생물학 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the synthetic biology market size was valued at USD 19.75 billion in 2025 and estimated to grow from USD 23.53 billion in 2026 to reach USD 56.48 billion by 2031, at a CAGR of 19.14% during the forecast period (2026-2031).

This report is Segmented by Product (Core Products, Enabling Products, and Enabled Products), Application (Healthcare, Chemicals (Including Biofuels), Food and Agriculture, and Other Applications (Biosecurity, Energy, and Environment)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Global Synthetic Biology Market Trends and Insights

Government & VC Funding Surge

Large-scale public programs are deepening the capital pool that supports biomanufacturing build-outs. The United States enacted a USD 15 billion National Biotechnology Initiative Act to meet 30% of domestic chemical demand through bio-based production by 2040 . China committed USD 4.17 billion in 2024 for biomanufacturing infrastructure, signaling technology sovereignty priorities. Horizon Europe's SYNBEE project nurtures start-ups across 25 nations, while venture funding has remained above pre-pandemic levels according to SynBioBeta. This confluence of public and private capital shortens the "valley of death" from lab bench to pilot plant, accelerating time-to-market across the market.

Falling Cost Curve for Gene Synthesis

Enzymatic DNA synthesis now delivers multi-kilobase constructs in days instead of weeks. Ansa Biotechnologies' platform synthesizes sequences exceeding 1,000 bp today and targets 10,000 bp capability by 2025 . Evonetix's semiconductor-based chips fabricate gene-length fragments 10 times faster than traditional phosphoramidite chemistry. Benchtop synthesizers from Kilobaser and Telesis Bio further democratize access for smaller labs. These innovations cut iteration costs for metabolic-engineering and protein-optimization projects, reinforcing demand across the synthetic biology market.

Dual-Use Bio-Threat Regulation Drag

Compliance burdens grow as policymakers tighten genetic-material screening. SecureDNA screens every order over 30 bp against pathogen databases while preserving customer confidentiality, adding cost and processing time. China's biosafety framework imposes strict oversight of engineered microbes yet aims to support innovation. Europe postponed its Biotech Act until Q3 2026, prolonging uncertainty. Frontiers research warns that AI-enabled bio-automation may outpace legislative cycles, requiring new governance models. Smaller firms in the synthetic biology market often lack the regulatory-affairs bandwidth to navigate these regimes, slowing product launches.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Driven Protein Design Adoption
2. Breakthroughs in Gene-Editing Platforms Expanding Addressable Applications
3. Corporate Net-Zero Mandates Driving Demand for Bio-Based Chemicals, Fuels, and Materials
4. Talent Bottleneck in Bio-Informatics Engineers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Core Products accounted for 47.92% of 2025 revenue as DNA/RNA synthesizers and gene-editing kits formed the indispensable infrastructure of laboratory workflows. Evonetix's chip-based synthesizer exemplifies hardware innovation, cutting synthesis times by a factor of 10 and anchoring recurring consumables demand. The synthetic biology market size for Core Products is expected to grow steadily, supported by continuous upgrades to accuracy and throughput.

Enabling Products-encompassing oligonucleotides, cloning vectors, and cell-free systems-are forecast to grow at a 19.91% CAGR through 2031, the fastest among product classes. Twist Bioscience's participation in AI safety consortia underscores the strategic importance of secure DNA sourcing. The first synthetic yeast genome and programmable cell-free protein factories reflect rising complexity needs, which magnify consumables volume across the synthetic biology market.

Genome Engineering held 33.21% of synthetic biology market share in 2025, buoyed by widespread CRISPR-Cas9 adoption and emergent alternatives like TIGR. Commercialization milestones such as CASGEVY validate therapeutic revenue pools. Regulatory precedents are encouraging industrial and agricultural genome-editing initiatives, reinforcing leadership of this technology segment.

Bioinformatics & CAD Tools will expand at a 19.56% CAGR, transforming empirical tinkering into algorithmically guided engineering. Researchers describes CodonTransformer's multi-species optimization framework that shortens path-to-hit timelines . As AI models scale, subscription software revenues are set to rise faster than reagent sales, reshaping the synthetic biology market size distribution among value-chain players.

Complete Report Scope:

• By Product
  • Core Products
    • DNA/RNA Synthesizers
    • Gene Editing Kits & Enzymes
  • Enabling Products
    • Oligonucleotides
    • Cloning Vectors
  • Enabled Products
    • Cell-Free Systems
    • Engineered Micro-organisms
• By Technology
  • Genome Engineering
  • DNA/RNA Synthesis
  • Bioinformatics & CAD Tools
  • Bioprocessing & Automation
• By Application
  • Healthcare
    • Drug Discovery
    • Gene & Cell Therapy
  • Chemicals & Biofuels
    • Specialty Chemicals
    • Advanced Biofuels
  • Food & Agriculture
    • Alternative Proteins
    • Crop Trait Engineering
  • Other (Bio-security, Environment, Data Storage)
• By End-User
  • Industrial Biotech Companies
  • Pharma & Biopharma
  • Academic & Research Institutes
  • Defense & Government Labs
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East
    • GCC
    • Rest of Middle East
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.12% revenue share in 2025. The USD 15 billion federal biomanufacturing commitment anchors capacity build-outs, while venture capital and established R&D clusters sustain start-up formation. Ginkgo Bioworks' platform partnerships and Thermo Fisher Scientific's USD 40-50 billion M&A war chest illustrate consolidation and scale advantages. Nevertheless, U.S. firms face talent bottlenecks in bio-informatics and the compliance load of overlapping federal and state rules, factors that could modulate synthetic biology market growth in the region.

Asia-Pacific is the fastest-expanding region at 21.7% CAGR. China has overtaken Europe in high-impact biotech papers and patents, supported by USD 4.17 billion in 2024 investments and further allocations slated for 2025. Shanghai's biotech hub leverages co-located manufacturing infrastructure and subsidy programs to accelerate commercialization. Price-competitive production capabilities position the region as a leading export platform, reinforcing its influence on the global synthetic biology market.

Europe combines robust sustainability policy with fragmented regulatory execution. The Circular Bio-Based Europe initiative directs USD 2.2 billion toward 15 biorefineries employing 165,000 workers. Horizon Europe's SYNBEE extends entrepreneur support to 25 nations. Delays in the EU Biotech Act, however, prolong uncertainty and may slow project financing. Companies like Insempra have raised USD 20 million to scale bio-based ingredients for cosmetics even amid cautious capital markets. Despite hurdles, Europe's circular-economy ethos secures long-term relevance within the synthetic biology market.

1. Thermo Fisher Scientific
2. Danaher (IDT & Cytiva)
3. Illumina
4. Genscript
5. Twist Bioscience
6. Amyris
7. Gingko Bioworks
8. Precigen
9. Novozymes
10. DSM-Firmenich
11. Zymergen
12. Synthetic Genomics (Viridos)
13. New England Biolabs
14. Inscripta
15. Benchling
16. Oxford Nanopore
17. Evonetix
18. Prokarium
19. Arzeda
20. Deep Genomics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Government & VC funding surge
  • 4.2.2 Falling cost curve for gene synthesis
  • 4.2.3 AI-driven protein design adoption
  • 4.2.4 Strategic moves by agriculture and food majors to secure engineered proteins and next-gen crops for supply-chain resilience
  • 4.2.5 Breakthroughs in gene-editing platforms expanding addressable applications
  • 4.2.6 Corporate net-zero mandates driving demand for bio-based chemicals, fuels, and materials
• 4.3 Market Restraints
  • 4.3.1 Dual-use bio-threat regulation drag
  • 4.3.2 Talent bottleneck in bio-informatics engineers
  • 4.3.3 Limited DNA data-storage standards
  • 4.3.4 Societal and ethical concerns over GMO adoption,
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value / USD)

• 5.1 By Product
  • 5.1.1 Core Products
    • 5.1.1.1 DNA/RNA Synthesizers
    • 5.1.1.2 Gene Editing Kits & Enzymes
  • 5.1.2 Enabling Products
    • 5.1.2.1 Oligonucleotides
    • 5.1.2.2 Cloning Vectors
  • 5.1.3 Enabled Products
    • 5.1.3.1 Cell-Free Systems
    • 5.1.3.2 Engineered Micro-organisms
• 5.2 By Technology
  • 5.2.1 Genome Engineering
  • 5.2.2 DNA/RNA Synthesis
  • 5.2.3 Bioinformatics & CAD Tools
  • 5.2.4 Bioprocessing & Automation
• 5.3 By Application
  • 5.3.1 Healthcare
    • 5.3.1.1 Drug Discovery
    • 5.3.1.2 Gene & Cell Therapy
  • 5.3.2 Chemicals & Biofuels
    • 5.3.2.1 Specialty Chemicals
    • 5.3.2.2 Advanced Biofuels
  • 5.3.3 Food & Agriculture
    • 5.3.3.1 Alternative Proteins
    • 5.3.3.2 Crop Trait Engineering
  • 5.3.4 Other (Bio-security, Environment, Data Storage)
• 5.4 By End-User
  • 5.4.1 Industrial Biotech Companies
  • 5.4.2 Pharma & Biopharma
  • 5.4.3 Academic & Research Institutes
  • 5.4.4 Defense & Government Labs
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East
    • 5.5.4.1 GCC
    • 5.5.4.3 Rest of Middle East
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Thermo Fisher Scientific
  • 6.3.2 Danaher (IDT & Cytiva)
  • 6.3.3 Illumina
  • 6.3.4 GenScript
  • 6.3.5 Twist Bioscience
  • 6.3.6 Amyris
  • 6.3.7 Gingko Bioworks
  • 6.3.8 Precigen
  • 6.3.9 Novozymes
  • 6.3.10 DSM-Firmenich
  • 6.3.11 Zymergen
  • 6.3.12 Synthetic Genomics (Viridos)
  • 6.3.13 New England Biolabs
  • 6.3.14 Inscripta
  • 6.3.15 Benchling
  • 6.3.16 Oxford Nanopore
  • 6.3.17 Evonetix
  • 6.3.18 Prokarium
  • 6.3.19 Arzeda
  • 6.3.20 Deep Genomics

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment